Anti-Rheumatic Drugs - Western Asia

Western Asia

In Western Asia, the revenue in the Anti-Rheumatic Drugs market is estimated to reach US$0.56bn by the year 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 0.70%, leading to a market volume of US$0.58bn by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$34,700.00m in 2024.
Despite the high prevalence of rheumatic diseases in Western Asia, the market for anti-rheumatic drugs remains relatively underdeveloped.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Western Asia has been experiencing significant growth in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis and other rheumatic diseases are the primary customers of Anti-Rheumatic Drugs in Western Asia. These patients prefer drugs that are effective in reducing inflammation and pain, while also being affordable and easily accessible.

Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in Western Asia is the increasing demand for biologic drugs. Biologics are considered to be more effective than traditional disease-modifying anti-rheumatic drugs (DMARDs) in treating rheumatic diseases. However, they are also more expensive and may not be affordable for many patients. As a result, there is a growing demand for biosimilars, which are cheaper versions of biologics.Another trend in the market is the growing use of combination therapies. Rheumatologists in Western Asia are increasingly prescribing a combination of DMARDs and biologics to achieve better outcomes for their patients. This trend is expected to continue in the coming years, as more clinical evidence is generated to support the use of combination therapies.

Local special circumstances: One of the unique features of the Anti-Rheumatic Drugs market in Western Asia is the high prevalence of consanguineous marriages. This has led to a higher incidence of genetic disorders, including some forms of rheumatic diseases. As a result, there is a higher demand for Anti-Rheumatic Drugs in this region compared to other parts of the world.Another local circumstance is the relatively low healthcare spending in many countries in Western Asia. This has led to a situation where many patients cannot afford the cost of biologics and other expensive drugs. As a result, there is a growing demand for more affordable treatment options, including biosimilars.

Underlying macroeconomic factors: The Anti-Rheumatic Drugs market in Western Asia is being driven by several underlying macroeconomic factors. One of the key drivers is the growing prevalence of rheumatic diseases in the region. This is partly due to the high incidence of consanguineous marriages, as well as other factors such as aging populations and changing lifestyles.Another macroeconomic factor is the increasing availability of healthcare services in many countries in Western Asia. As healthcare systems become more developed, there is a growing demand for more advanced treatments, including biologics and other innovative therapies.Finally, the Anti-Rheumatic Drugs market in Western Asia is also being influenced by broader global trends, such as the increasing focus on personalized medicine and the growing use of digital technologies in healthcare. These trends are expected to continue to shape the market in the coming years, as new therapies and technologies are developed to meet the needs of patients in Western Asia and beyond.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.